On-Topic Virtual Roundtable: Multidisciplinary Approaches and Thoughts on the Care of HER2+ Breast Cancer
Release Date: February 28, 2021
Expiration Date: February 27, 2022
Target Audience
The target audience for this activity is clinicians/HCPs who treat patients with HER2+ breast cancer inclusive of a multidisciplinary care team (community and academic medical oncologists, surgeons, radiation oncologists, experts in diagnostic imaging, pathologists, oncology nurses, nurse practitioners, genetic counselors, and pharmacists).
Learning Objectives
After participating in this activity, participants should be better able to:
- Discuss the role of HER2 in the pathogenesis of breast cancer and the rationale for using HER2-directed therapies in patients with this disease subtype
- Evaluate clinical trial data of current and emerging therapies for patients with HER2+ breast cancer
- Develop strategies using a multidisciplinary approach with physicians and nurse/advanced practitioners to address complicated cases of HER2+ breast cancer
Topics of Discussion
Introduction & The Role of HER2 in Breast Cancer
It Takes a Village: Optimizing the Breast Cancer Care Team
Treating Metastatic HER2+ Breast Cancer
Mitigating and Managing Adverse Events
Key Takeaways
Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty
Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Cancer Program
Texas Oncology and US Oncology Network
Dallas, Texas
Consulting Fees: AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeutics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals
Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee
Consulting Fees: Pfizer Inc, Genentech/Roche, Lilly, Puma Biotechnology, Daiichi Sankyo, Mersana, Boehringer Ingelheim, AstraZeneca, Novartis, Silverback Therapeutics, Black Diamond, CytomX Therapeutics, Dantari, H3 Biomedicine, Merck, Novartis, Seattle Genetics, Eisai
Grants/Research Support: AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millennium, TapImmune Inc., Lilly, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Takeda, Macrogenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, Inventis Bio, Deciphera, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback, Seattle Genetics, Puma Biotechnology, Compugen, G1 Therapeutics, Karyopharm Therapeutics, Torque, Dana-Farber Cancer Hospital, Infinity Pharmaceuticals, Onconova Therapeutics
Other Financial or Material Support: AstraZeneca, Lilly, Pfizer, Puma Biotechnology, Daiichi Sankyo
Marissa Marti, APRN, AGNP-C, AOCNP
Nurse Practitioner
Texas Oncology
Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Consulting Fees: Biotheranostics, Inc., Novartis, Puma Biotechnology, Research to Practice, i3 Health
Patient Advocates & Breast Cancer Survivors
Julia Maués
No relevant financial relationships to disclose
Sheila McGlown
No relevant financial relationships to disclose
Planning Committee
The following planning committee members have nothing to disclose except for the following:
Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies
Bio Ascend: Chloe Dunnam, Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP
Method of Participation
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must:
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Disclosure Declaration
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
Disclaimers
All information contained within this activity is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained in this site. No single reference or service can take the place of medical training, education and experience. This web site does not define a standard of care, nor is it intended to dictate an exclusive course of management. This information should not substitute for a visit or consultation with a health care provider.
Please be aware that by participating in this enduring activity, you consent to your name being used without compensation, for use in any and all media, whether now known or hereafter devised, for eternity, and you release Bio Ascend LLC, its parent company, successors, assigns and licensees from any liability whatsoever of any nature.
Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo
Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.